scholarly journals The effect of the phytocomplex Renotineх® on postoperative period after external shock wave lithotripsy in patients with urolithiasis

2021 ◽  
Vol 11 (1) ◽  
pp. 49-54
Author(s):  
Aleksandr I. Neymark ◽  
Boris A. Neymark ◽  
Nikolay A. Nozdrachev ◽  
Michail Y. Gatkin ◽  
Yulia S. Fursa
Keyword(s):  
Shock Wave ◽  
Extracorporeal Shock Wave Lithotripsy ◽  
Shock Wave Lithotripsy ◽  
Comparison Group ◽  
Postoperative Management ◽  
Main Group ◽  
Preoperative Preparation ◽  
Effective Discharge ◽  
Extracorporeal Shock Wave ◽  
Nephroprotective Effect

INTRODUCTION: Phytopreparations are one of the leading medicines used as preoperative preparation and postoperative management in patients with urolithiasis. THE AIM of the study was to evaluate the nephroprotective effect of Renotinex in patients with urolithiasis after extracorporeal shock wave lithotripsy (ESWL). MATERIALS AND METHODS: The study included 86 patients (43 in the main and the comparison group) with urolithiasis with localization of the stone in the renal pelvis without disturbing the outflow of urine. All patients underwent extracorporeal shock wave lithotripsy (ESWL). After ESWL patients in both groups received spasmodic, anti-inflammatory, antibacterial therapy. Patients of the main group additionally received Renotinex 2 capsules 3 times a day for 14 days before and 14 days after surgery. RESULTS: During the observation a more effective discharge of calculus fragments was noted in patients of the main group while taking the phytocomplex Renotinex, as well as less pronounced damage and faster recovery of the renal parenchyma after ESWL according to the level of enzimuria. CONCLUSION: The results of the study indicate the feasibility of prescribing the phytocomplex Renotinex for nephroprotective and lithokinetic therapy in patients after ESWL.

scholarly journals Combined (citrate and herbal) drug uriklar in extracorporeal shock wave lithotripsy and metaphylaxis of urolithiasis

2018 ◽  
Vol 8 (1) ◽  
pp. 19-25
Author(s):  
Aleksandr Yu Shestaev ◽  
Vladimir V Protoshchak ◽  
Mikhail V Paronnikov ◽  
Artyem O Kiselev
Keyword(s):  
Shock Wave ◽  
Urinary Tract ◽  
Extracorporeal Shock Wave Lithotripsy ◽  
Shock Wave Lithotripsy ◽  
Main Group ◽  
Urinary Stones ◽  
Control Group ◽  
Total Efficiency ◽  
Herbal Drug ◽  
Extracorporeal Shock Wave

The aim of the study was to study the clinical efficiency and safety of the drug uriklar in extracorporeal shock wave lithotripsy (ESWL) and early metaphylaxis of urolithiasis. Materials and methods. 45 patients were included in the prospective study. The patients were divided into two groups. The main group consisted of 25 patients, they received uriklar 1 capsule three times a day for one month before and three after ESWL. The control group included 20 patients who underwent ESWL only. Uriklar is combined drug with citrate and herbal components. Results. The total efficiency of ESWL was 92% in I group versus 75% in control group. Among the patients of the main group, the frequency of renal colic after ESWL was 24% (6 patients), while in the control group colic occurred in 9 patients (45%). The severity of pain syndrome was of 5.12 ± 2.1 in I group and of 7.48 ± 2.2 and in II group (p < 0.05). Uriklar in the first group of patients increased the pH of urine and the excretion of citrate significantly and decreased excretion of uric acid. After 3 months, the vast majority of patients (n = 24, 96%) of the main group underwent curing of the urinary tract, and daily diuresis remained at 2.3 ± 0.3 l/day. Conclusions. The uriklar taking increases the fragmentation of urinary stones and the elimination of the resulting fragments from the urinary tract, promotes the normalization of metabolic disorders, and effectively eliminates infectious-inflammatory complications of urolithiasis. It is also well-tolerated and has no side effects. (For citation: Shestaev AYu, Protoshchak VV, Paronnikov MV, Kiselev AO. Combined (citrate and herbal) drug uriklar in extracorporeal shock wave lithotripsy and metaphylaxis of urolithiasis. Urologicheskie vedomosti. 2018;8(1):19-25. doi: 10.17816/uroved8119-25).

Sign in / Sign up

Export Citation Format

Share Document